OTC Markets OTCPK - Delayed Quote USD

Zealand Pharma A/S (ZLDPF)

101.51

0.00

(0.00%)

At close: January 31 at 3:00:00 PM EST

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January 13, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securit

GlobeNewswire 18 days ago

ZLDPF
0.00%
High Growth Tech Stocks to Watch in January 2025

As we enter January 2025, global markets have shown mixed performance, with the S&P 500 and Nasdaq Composite closing out a strong year despite recent fluctuations. Economic indicators such as the Chicago PMI and revised GDP forecasts highlight ongoing challenges for small-cap companies, but positive trends in jobless claims provide some optimism. In this environment, identifying high-growth tech stocks requires focusing on companies with robust innovation capabilities and adaptability to...

Simply Wall St. 23 days ago

ZLDPF
0.00%
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Press Release – No. 2 / 2025 Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity Copenhagen, Denmark, January 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Steven R. Smith, MD, has joined Zealand Pharma as Senior Global Medical Advisor – Obesity, as of January 1, 2025. Steven will report to David Kendall, Chief

GlobeNewswire 24 days ago

ZLDPF
0.00%
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Press Release – No. 1 / 2025 Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th Copenhagen, Denmark, January 6, 2025 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will present an overview of the company at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA at 2:15 p.m. PT (11:15

GlobeNewswire 25 days ago

ZLDPF
0.00%
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 23 December 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:

GlobeNewswire last month

ZLDPF
0.00%
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand Pharma’s application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide.Zealand Pharma will continue the dialogue with the FDA to align on the path toward obtaining regulatory approval in the U

GlobeNewswire last month

ZLDPF
0.00%
2 Weight Loss Stocks That Are Screaming Buys in December

With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines. Zealand Pharma (OTC: ZLDP.F) is a biotech with a pipeline that's full of promising clinical-stage weight-loss programs, among other indications. In particular, its lead anti-obesity program, a molecule called survodutide, is in phase 3 clinical trials right now, and it's unique in the sense that no weight-loss drug on the market right now utilizes the exact same mechanism of action.

Motley Fool last month

LLY

ZEAL.CO
Exploring Top High Growth Tech Stocks For Potential Portfolio Enhancement

In recent weeks, global markets have experienced mixed performances with major U.S. indexes like the S&P 500 and Nasdaq Composite continuing to hit record highs, while smaller-cap indices such as the Russell 2000 saw declines after a period of outperformance. This divergence highlights the ongoing rally in growth stocks, particularly within sectors like information technology and consumer discretionary, which have shown significant gains amid varied economic indicators such as job growth...

Simply Wall St. last month

ZLDPF
0.00%
6645.TW
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the first participant has been enrolled in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity.The Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Completion of enrollment into ZUPREME-1 is expected in th

GlobeNewswire last month

ZLDPF
0.00%
Zealand Pharma to participate in the Jefferies London Healthcare Conference

Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies London Healthcare Conference at 9:30 a.m. GMT (10:30 a.m. CET) on Thursday, November 21, 2024. A liv

GlobeNewswire 2 months ago

ZLDPF
0.00%
Exploring High Growth Tech Stocks In November 2024

Global markets have recently experienced significant shifts, with U.S. stocks rallying to record highs following a Republican electoral sweep, leading to expectations of accelerated earnings growth and reduced regulatory burdens. Amidst these developments, the small-cap Russell 2000 Index has shown impressive gains, highlighting the potential opportunities within high-growth tech stocks as investors seek companies that can thrive under favorable economic policies and lower corporate taxes.

Simply Wall St. 2 months ago

1415.HK

ZLDPF
0.00%
Zealand Pharma AS (ZLDPF) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...

Zealand Pharma AS (ZLDPF) showcases promising trial results and strategic partnerships while navigating high R&D expenses and regulatory hurdles.

GuruFocus.com 2 months ago

ZEAL.CO
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates

Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of 9.68% and 75.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ZEAL.CO
Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial position. Presented extremely encouraging weight loss and tolerability data with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial) at ObesityWeek 2024Announced positive topline results with GLP-1R/GLP-2R dual agonist dapiglutide from Part 1 of P

GlobeNewswire 2 months ago

ZLDPF
0.00%
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 7, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for t

GlobeNewswire 2 months ago

ZLDPF
0.00%
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

The future of the weight loss market might not revolve around GLP-1 drugs.

Motley Fool 3 months ago

ZEAL.CO
FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants

The regulator sought additional analyses from existing continuous glucose monitoring data collected during Phase III trials.

Pharmaceutical Technology 3 months ago

ZEAL.CO
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for dasiglucagon in CHI for up to three weeks of dosing due to the timing of a third-party manufacturing facility reinspectionThe reinspection of the facility was completed in August/September 2024 for which a new inspection classification is pendingZealand remains committed to working with

GlobeNewswire 3 months ago

ZLDPF
0.00%
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II study Boehringer launches two Phase III studies of survodutide, L

GlobeNewswire 3 months ago

ZLDPF
0.00%
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end

GlobeNewswire 3 months ago

ZLDPF
0.00%

Performance overview

Return	ZLDPF	OMX Copenhagen 25 Index
YTD	-0.83%	-0.51%
1-year	+44.66%	-4.07%
3-year	+340.39%	+2.11%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zealand Pharma A/S (ZLDPF)

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

High Growth Tech Stocks to Watch in January 2025

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

2 Weight Loss Stocks That Are Screaming Buys in December

Exploring Top High Growth Tech Stocks For Potential Portfolio Enhancement

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Exploring High Growth Tech Stocks In November 2024

Zealand Pharma AS (ZLDPF) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...

Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

Performance overview